Sequelae and Immunopathology of Ebola Virus Infections
Closed Pre-Solicitation Posted
- Solicitation number
- FDA-RFP-20-1225983
- Agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541690 Other Scientific and Technical Consulting Services
- PSC
- Q516 Medical- Pediatric
- Place of performance
- Philadelphia PA 19104 USA
Notice details come from SAM.gov. Updated .
Notice text
The current contract is a study focused on Sequelae and Immunopathology of Ebola Virus Infections. This modification is necessary to respond to the ongoing 2019-nCoV virus (nCoV) outbreak and leverages the technology and methodology for examining Ebola sequelae and Zika immunopathology to extend analysis and gather critical information about the nature of nCoV virus infection. This work aims to characterize the effects of nCoV virus infection using samples from non-human primate (NHP) animal models and human tissues (pending availability) to empower future regulatory decision making. Stanford shall apply a set of technologies for high parameter antibody-based profiling of blood and tissues (CyTOF, CODEX) along with viral nucleic acid detection in situ (viralMIBI).
Files
| File | Type | Posted |
|---|---|---|
| NOI 1225983 3520 .pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity